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Statement of Translational Relevance 
Here, we have shown that non homologous end joining is critically important in determining 
sensitivity to PARP inhibitors. 40% of ovarian cancers tested had defective NHEJ and this 
rendered them resistant to PARP inhibition, irrespective of their Homologous Recombination 
status. 
To date, the priority for developing accurate biomarkers for PARP sensitivity has focussed on 
developing surrogate markers for HR status. This work suggests that this will not be enough 
and a more detailed assessment of the DNA damage response, including NHEJ status, is 
likely to be required. 
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Abstract 
Purpose: DNA damage defects are common in ovarian cancer and can be used to stratify 
treatment. Although most work has focussed on Homologous Recombination (HR), DNA 
double strand breaks are repaired primarily by non-homologous end joining (NHEJ). Defects 
in NHEJ have been shown to contribute to genomic instability and have been associated with 
the development of chemoresistance.  
Experimental Design: NHEJ was assessed in a panel of ovarian cancer cell lines and 47 
primary ascitic derived ovarian cancer cultures, by measuring the ability of cell extracts to 
end-join linearized plasmid monomers into multimers. mRNA and protein expression of 
components of NHEJ was determined using RT-qPCR and western blotting. Cytotoxicities of 
cisplatin and the Poly(ADP-ribose) polymerase-1 (PARP) inhibitor rucaparib were assessed 
using sulforhodamine B (SRB) assays. HR function was assessed using H2AX/RAD51 foci 
assay.  
Results: NHEJ was defective (D) in 4 of 6 cell lines and 20 of 47 primary cultures. NHEJ 
function was independent of homologous recombination (HR) competence (C). NHEJD 
cultures were resistant to rucaparib (p=0.0022). When HR and NHEJ functions were taken 
into account, only NHEJC/HRD cultures were sensitive to rucaparib (compared to 
NHEJC/HRC p=0.034, NHEJD/HRC p=0.0002, and NHEJD/HRD p=0.0045). The DNA-PK 
inhibitor, NU7441 induced resistance to rucaparib (p=0.014) and HR function recovery in a 
BRCA1 defective cell line.  
Conclusion: This study has shown that NHEJ is defective in 40% of ovarian cancers, which is 
independent of HR function and associated with resistance to PARP inhibitors in ex vivo 
primary cultures.  
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Introduction 
Double strand breaks (DSBs) [1], the most lethal forms of DNA damage, are repaired by two 
main pathways: non-homologous end-joining (NHEJ) and homologous recombination (HR). 
These pathways are distinct in that HR copies identical DNA sequences from sister 
chromatids resulting in error-free repair [2], whilst NHEJ joins the broken DNA ends with 
limited processing [3]. In vitro studies have demonstrated that complementary DNA ends are 
joined in an efficient and accurate manner by NHEJ [4, 5]. However, the modification 
required for partially or completely incompatible DNA ends results in losses of sequence at 
the resultant junctions, such that NHEJ is potentially a mutagenic process [3, 6]. More recent 
studies have demonstrated an alternative end joining mechanism (A-EJ), which uses regions 
of microhomology at internal sites on the DNA substrate. Unlike HR, A-EJ is inherently 
error-prone as the use of microhomology leads to deletions of sequences from the strand 
being repaired, and to chromosomal translocations [7, 8]. This mechanism has been 
suggested to function in the absence of NHEJ [9-14] and more recently in absence of HR [7, 
8]. 
NHEJ has been demonstrated to function throughout the cell cycle [1, 15]. The NHEJ 
pathway is initiated by the binding of the Ku heterodimer (Ku70 and Ku80) to DSBs, and the 
subsequent association and autophosphorylation of the DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) [16]. This DNA-PK complex facilitates ligation by recruitment 
of the XRCC4/LIG4 complex. Mutations in NHEJ components are associated with 
immunodeficiency and developmental abnormalities [17, 18] as well as cancers [6, 19-22], 
underscoring the importance of the NHEJ pathway in maintaining genome integrity. 
DNA damage repair is increasingly recognized as an important determinant of response to 
cancer therapeutics. This interest was initially provoked by the paradigm shifting discovery 
that inhibition of base excision repair with Poly(ADP-ribose) polymerase-1 (PARP-1) 
inhibitors (PARPi) was synthetically lethal in HR defective (HRD) tumours. PARPi were 
therefore selectively targeting the defect arising in the tumour, but not in normal tissues [23-
27]. In epithelial ovarian cancer (EOC) HRD is reported in 50% of cases [28] and evidence is 
building for the efficacy of PARPi. This has been assumed to be as a result of synthetic 
lethality, with PARPi preventing effective base excision repair leading to stalled replication 
forks which in turn could not be repaired by homologous recombination. However a number 
of studies also indicate a connection between components of the NHEJ pathway and PARP-1 
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[29-35], culminating in the suggestion by Patel et al that dysfunctional NHEJ is important in 
generating genomic instability in PARPi treated, homologous recombination defective, cells 
[36]. Moreover, they also demonstrated that inhibition of DNA-PK results in HR function 
recovery and PARPi resistance in vitro [37].  
The suggestion that NHEJ status is important in determining sensitivity to PARP inhibitors is 
in keeping with evidence that NHEJ is a fast pathway which is the pathway of choice for the 
repair of DSBs with HR only being employed for unrepaired DSBs [38]. 
 
The incidence of NHEJ dysfunction has not been explored in primary EOC to date.  Here we 
demonstrate that more than 40% of primary ovarian cancer (PCO) cultures are NHEJ 
defective (NHEJD), which is associated with resistance to rucaparib ex vivo. 
Materials and Methods 
Cell culture  
Ethical approval was granted (12/NW/0202) for the collection of ascites from consented 
patients undergoing surgery for EOC at the Queen Elizabeth Hospital, Gateshead, UK. 
Clinical details were recorded and specimens registered and handled in accordance with the 
Human Tissue Act. Samples were assigned a reference number to retain anonymity. 
PCO cultures were generated and maintained as previously described [39, 40].  Briefly 20ml 
of ascites was added to 20ml of warmed Sigma RPMI 1460 HEPES modified culture medium 
supplemented with 20% v/v fetal calf serum and 100µl/ml penicillin and streptomycin in T75 
flasks and incubated at 37°C, 5% CO2 humidified air.  
Cell lines 
All cell lines, unless stated otherwise, were grown in RPMI 1640 media supplemented with 
10% FBS and 100 units/ml penicillin/streptomycin incubated at 37°C in 5% CO2. V3 (DNA-
PKCS defective) and V3YAC cells (V3 cells complemented with human DNA-PKCS) were a 
kind gift from Professor Jeggo. V3YAC cells were grown in full medium with G418 (400 
µg/ml). A2780, a human ovarian carcinoma cell line and CP70, MMR deficient variant of 
A2780, 5-fold resistant to cisplatin relative to the parental A2780 were a kind gift from Prof. 
R. Brown (Cancer Research UK Beatson Laboratories, Glasgow, Scotland). SKOV-3, 
OVCAR-3, IGROV-1, and MDAH are all human ovarian adenocarcinoma cell lines and were 
purchased from American Type Culture Collection (ATCC, VA, USA). PEO1 cell line was 
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derived from a poorly differentiated serous adenocarcinoma and PEO4 cell line derived from 
the same patient after clinical resistance developed to chemotherapy. Both were purchased 
from the European Collection of Cell Cultures.  
OSEC2 and OSEC4 cell lines developed at Newcastle University from normal ovarian 
surface epithelium using a temperature sensitive SV-40 large T antigen construct were 
incubated at 33oC [41].  
UWB1-289 is a BRCA1-null human EOC cell line derived from papillary serous ovarian 
carcinoma was cultured in 50% RPMI 1640 media supplemented with 10% FBS and 100 
units/ml penicillin/streptomycin and 50% (v/v) MEBM BulletKit media (Lonza) 
supplemented with 10% FBS. UWB1-289-BRCA1 is derived from UWB1-289 cells in which 
BRCA1 was restored were cultured in full media with 400 µg/ml G418. Both were obtained 
from American Type Culture Collection. 
Cell-free extract preparation 
Cell extracts were prepared as previously described [6]. Briefly, three T175 flasks at 80% 
confluence were trypsinised, lysed in 500µl of hypotonic buffer and homogenized. After the 
addition of 0.5 vol of high salt buffer, the extracts were centrifuged for 56 min at 70,000RPM 
(213,000g) at 4°C in a Beckman TLA120.2 rotor. Protein concentration was determined 
using the BSA protein assay according to manufacturer's instructions (ThermoScientific). 
Samples were snap-frozen and stored at −80°C. 
DNA end-joining assay 
Vectors which on digestion with BstXI yielded a 3.2 kb plasmid and 1.2 kb λ fragment with 
either compatible (Co) (CCACTAAG_GTGG and GGTG_ATTCCACC) or 2 base pair (2I) 
(CCACTAAG_GTGG and GGTG_AAACCACC) and 4 base pair (4I) (CCACTAAG_GTGG 
and GGTG_TAAGCACC) incompatible ends. Vectors were kindly donated by Dr Ann Kiltie 
(Oxford, UK). DNA fragments were gel-purified using spin columns (Qiagen, UK). End-
joining reactions were carried out as previously described [6] with 45 μg protein extract and 
100ng DNA substrate for 2.5 hours. DNA was extracted with Tris-buffered 
phenol/chloroform/isoamyl alcohol. Analysis was performed by agarose (0.7%) gel 
electrophoresis and GelRed (VWR) staining. Image capture was carried out using G:Box and 
GeneSnap system, and analysed using GeneTools (SynGene). 
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PCR amplification of rejoined products 
For the analysis of joined products, end-joining reactions were ethanol-precipitated and 
amplified using ThermoPrimeTaq with ReadyMix PCR buffer (Thermo Scientific, UK) in the 
presence of internal plasmid primers pFOR (5′-CCGGCGAACGTGGCGAGAAAG) and 
pREV (5′-GACTGGAAAGCGGGCAGTGAG) for 40 cycles (30s at 94°C, 30s at 55°C, 30s 
at 72°C, full length product size 551 bp). Analysis was performed by agarose (1%) gel 
electrophoresis and GelRed staining.  
Intracellular end joining assay 
Plasmid pGL2 (Promega) was linearized using either HindIII or EcoRI, linearization was 
confirmed by agarose gel electrophoresis. The linearized DNA was purified using the 
QIAquick PCR Purification Kit, (Qiagen), dissolved in sterilized water, and transfected into 
cells using Lipofectamine LTX (Invitrogen) as per manufacturer’s instructions. The 
transfectants were harvested 48 hours after transfection and assayed for luciferase activity as 
described previously [42]. 
Homologous recombination assay 
Cells were seeded onto glass cover slips and treated with 2 Gy ionising radiation and 
rucaparib at 10 µM concentration for 24 hours to induce double strand breaks (DSB).  All 
experiments were performed alongside untreated controls with equivalent 0.1% DMSO. Cells 
were then fixed and rehydrated prior to staining with 1:100 mouse monoclonal anti-γH2AX 
(Upstate, Millipore Corp., USA) and 1:100 goat polyclonal anti-Rad51 (Calbiochem, EMD 
Biosciences, Inc., USA) antibodies with appropriate secondary fluorochrome conjugated 
antibodies, as previously described [43].  
Image J counting software [44, 45] was used to count γH2AX and Rad51 nucleic foci. Cells 
were classed as homologous recombination (HR) competent if there was more than a 2 fold 
increase in Rad51 foci after DNA damage, confirmed by a 2 fold increase in γH2AX.  
Reverse transcription and real time PCR  
Extraction of RNA was performed using an RNeasy Mini kit (Qiagen) as per manufacturer’s 
instructions. RNA was eluted in 30µl RNase-free water and quantified on the Nanodrop ND-
1000 Spectrophotometer (Lab tech International). 1.6µg of the total RNA was incubated at 
65˚C for 5 min followed by 37˚C for 5 min prior to addition of Promega MMLV-reverse 
Defective NHEJ function in ovarian cancer 
 
8 
transcriptase master mix (4µl 5x Moloney Murine Leukaemia Virus RT buffer, 2µl 4mM 
dNTPs, 1µl 50µM Oligo dT15and 0.3µl MMLV reverse transcriptase) and incubation at 37˚C 
for 1 hour followed by 95˚C for 5 min. 2µl of cDNA was loaded on to a 386 well plate in 
triplicate with Invitrogen SYBR green Master Mix (dNTPs, optimised buffer, UDG, ROX 
reference dye, AmpliTaq DNA polymerase UP and SYBR green ER dye) and the 2.5mM of 
the appropriate forward and reverse primers. Primers used were purchased from Sigma 
Aldrich, Primers sequences were - DNAPK-1 5’–CTAACTCGCCAGTTTATCAATC–3’; 
5’–TTTTTCCAATCAAAGGAGGG–3’; DNA-PK-2 5’–
GATCTGAAGAGATATGCTGTG–3’; 5’–GTTTCAGAAAGGATTCCAGG–3’; XRCC5 
5’-TTCATTCAGTGAGAGTCTGAG-3’; 5’-CGATTTATAGGCTGCAATCC-3’; XRCC6 
5’-AAGAAGAGTTGGATGACCAG-3’;  5’-GTCACTTCTGTATGTGAAGC-3’; LIG4 5’-
ATTTCTCCCGTTTTTGACTC-3’; 5’-GAATCTTCTCGTTTAACTGGC-3’; XRCC4-1 5’-
AGCTGCTGTAAGTAAAGATG-3’; 5’-CCAAGATTTCTTTGCATTCG-3’; XRCC4-2 5’-
CCAAGTAGAAAAAGGAGACAG-3’; 5’-GCTTTTCCTTTTCTTGAAGC-3’; XRCC4-3 
5’-CTAGAGAAAGTTGAAAACCCAG-3’; 5’-ATCGTCCTTGAACATCATTC–3’; 
GAPDH 5’–CGACCACTTTGTCAAGCTCA–3’; 5’–GGGTCTTACTCCTTGGAGGC–3’. 
Samples were run on an AbiPrism Applied Biosystems real time PCR machine for 10min at 
95˚C, 40 cycles (15s at 95˚C, 60s at 60˚C), 15s at 95˚C, 15s at 60˚C, 15s at 95˚C. Data was 
analysed using SDS2.3 software. 
Gel electrophoresis and western blotting 
Western blotting was assessed as previously described [46]. Briefly, 40µg of total protein 
from each samples was loaded and resolved by electrophoresis in 3-8% SDS-PAGE gradient 
gels (Biorad), and transferred to nitrocellulose membrane (Hybond C Membrane (GE 
Healthcare). Blots were then incubated using appropriate antibodies: DNA-PKcs, [1:500, at 
4oC, overnight (ON) (SantaCruz Biotechnology)]; Ku70 [1:800, at 4oC, ON (abcam, UK)]; 
Ku80 [1:800, at 4oC, ON (abcam, UK)]; XRCC4 [1:1000, at 4oC, ON (AbDSerotec, UK)]; 
Ligase IV [1:800, at 4oC, ON (Abcam, UK)]; GAPDH [1:3000, at room temperature (RT), 
for 1 hr (Santa Cruz)]. Followed by HRP-conjugated, Goat anti-rabbit or Goat anti-mouse 
IgG-HRP secondary antibody [1:1000 at RT, for 1 hr, (Dako, Cambridge, UK)]. Image 
capture and analysis was carried out using the Fuji LAS-300 Image Analyser System 
(FujiFilm). 
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SRB assay  
Sulforhodamine B (SRB) assay was used to assess cytotoxicity and cell growth as previously 
described [47]. Briefly, cells were seeded at a concentration of 1000 cells/well and after 
adherence, treated with different concentrations of rucaparib or cisplatin +/- 1µM of DNA-
PK inhibitor NU7441 for 10 days before fixation, staining and spectrophotometer assessment.  
Immunofluorescence 
Immunofluorescence experiments were carried out as previously described [43]. Briefly, cells 
were fixed after 24 hours with 10 µM rucaparib +/- 1 µM NU7441 and 2 Gy X-ray irradiation 
for HR assay or 1 hour after 2 Gy irradiation for pDNA-PKcs. The ƴH2AX, RAD51 or 
pDNA-PKcs foci were detected by immunofluorescence using appropriate antibodies. Anti-
phospho-histone ƴH2AX (Ser139) [1:100 dilution, at RT, for 1 hr (Upstate, Millipore 
Corporation, USA)]; Rabbit polyclonal anti-Rad51 [1:100 dilution, at 4oC, ON (Calbiochem, 
EMD Biosciences, Inc.)]; or DNA-PKcs phospho S2056 [1:500 dilution, at 4oC, ON (Abcam, 
UK)]. Followed by Alexa Fluor 546 Goat anti-mouse or 488 Goat anti- Rabbit IgG secondary 
antibody [1:1000 dilution at RT, for 1 hr, protected from light (Invitrogen, USA)]. Images 
were captured using a Leica DMR microscope and RT SE6 Slider camera Advanced Spot 
software version 3.408 (Diagnostic Instruments Inc. Sterling Heights, USA). Automated 
analysis using ImageJ software and a custom macro of foci in > 50 cells per field of view was 
carried out. 
PARP-1 activity  
PARP-1 activity was measured using a validated assay as previously described [48]. Briefly, 
PARP activity in 1000 permeabilised cells was maximally stimulated with a double-stranded 
oligonucleotide in the presence of excess NAD (350 μM) and the amount of ADP-ribose 
polymer formed quantified by immunoblot using anti-PAR antibody (clone 10H, from 
Professor Dr Alex Burkle University of Konstanz) by reference to a PAR standard curve 
(Enzo Life Sciences, Exeter, UK). Data is expressed as % PAR of L1210 control. 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 6.00 (GraphPad Software, 
La Jolla California USA) Unpaired student t tests or Mann–Whitney tests were used 
depending on a D'Agostino & Pearson omnibus normality test. Multiple comparisons were 
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performed using 1-way Anova with Tukeys multiple comparisons correction. All statistical 
tests were two-sided and considered statistically significant if the P value was less than 0.05.  
Results 
End-joining accuracy depends on DSB compatibility and NHEJ function 
A number of assays are described in the literature to assess NHEJ function [49]. Most of 
these assays only assess the rejoining of compatible ends, which does not represent the 
complexity of DNA DSBs that occur in cells. We therefore assessed rejoining of compatible 
(Co) and incompatible (2I - containing mismatches of two bases, and 4I - containing 
mismatches of 4 bases) vector ends following the addition of cell extracts. T4ligase ligated 
Co substrates, but incompatible substrates (2I and 4I) could not be joined without the addition 
of the appropriate DNA fragment which formed compatible ends with each 2I and 4I 
substrates (Figure 1.A). OSEC2 cells rejoined 34.8% of Co, 15.9% of 2I and 13.7% of 4I 
substrates (Figure 1.A-B). Addition of the DNA fragment increased the rejoining rate of 
incompatible (p<0.001 of 2I and p=0.0004 of 4I), but had no effect on rejoining of the 
compatible substrates. As both 2I and 4I had similar rejoining rates, assessment in cell lines 
and PCO panels was performed using Co and 2I substrates only. Comparison of rejoining in 
paired DNA-PK deficient and proficient cell lines demonstrated that whilst compatible ends 
are largely rejoined correctly, DNA-PK deficient V3 and M059J cells were unable to rejoin 
2I substrates (Figure 1.C). Furthermore addition of DNA-PK inhibitor NU7441 inhibited 
rejoining in DNA-PKcs proficient V3YAC cells, but had no effect on DNA-PKcs deficient 
V3 cells (Figure 1.D). 
DNA end joining in established EOC cell lines 
To ensure the cell free extract assay represented the cellular end joining accurately, NHEJ 
function was assessed in a panel of established cell lines using the cell extract and a cellular 
luciferase assay (Figure 2). Whilst the OSEC cell lines derived from normal ovarian 
epithelium were able to rejoin 2I ends accurately, four of the six EOC cell lines were unable 
to rejoin 2I substrates, thus indicating NHEJ deficiency. This correlated with the cellular end 
joining assay. Mean accurate cellular rejoining rate was 30.17%, 95% confidence interval 
(CI) = 25-37.6% by cell lines able to rejoin 2I substrates compared to 9.9%, 95% CI 4.39-
14.0, p=0.03 by cell lines unable to rejoin 2I substrates, when assessed using the luciferase 
cellular assay (Pearson correlation r = 0.79 p=0.007). We have previously demonstrated that 
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vector transfection into PCO cultures is not possible [39], therefore NHEJ was assessed in 
PCO cultures with the validated extract assay only. 
PCO cultures rejoin compatible DSBs, but 40% are unable to rejoin mismatched DSBs  
We next assessed end joining in a panel of primary ovarian cancer cultures. PCO cultures had 
a reduced end joining rate compared to NHEJ competent (NHEJC) control cell lines. There 
was significant inter-sample variability (range 5% to 39% of loaded DNA, Figure 3.A-B). 
PCR analysis of the junctions formed demonstrated that the rejoining of the Co substrate was 
accurate (Figure 3.C).  
We found that 20 of the 47 PCO cultures were NHEJD, as demonstrated by incubation with 
2I substrates producing either no products, or forming products of significantly smaller size 
(Example PCR product bands is shown in Figure 3.C). Furthermore, some cultures formed 
multiple bands of different sizes indicating loss of differing numbers of nucleotides. 
Extensive resection has been demonstrated to be due to use of microhomologies in this vector 
in the absence of a functional NHEJ pathway [6]. NHEJ competence was seen to be 
independent of culture growth rate, with a mean doubling time of 117 hours for NHEJC and 
115 hours for NHEJD cultures. Patient characteristics detailed in Supplementary Table ST1 
show that there was no significant difference between the NHEJC and NHEJD cultures in any 
of the clinical parameters assessed. 
Sensitivity to rucaparib but not cisplatin is dependent upon competent NHEJ function 
Sensitivity of rucaparib and cisplatin was assessed in the cell line panel and all primary 
cultures. In contrast to HRD association with increased rucaparib sensitivity, NHEJD cultures 
were resistant to rucaparib (p=0.0022, figure 4.A), as well as established cell lines (p<0.0001) 
(Figure 4.B). Furthermore, NU7441 induced resistance to rucaparib in the sensitive PCO 
cultures (p=0.014). When HR and NHEJ functions were taken into account, only 
NHEJC/HRD cultures were sensitive to rucaparib (compared to NHEJC/HRC p=0.034, 
NHEJD/HRC p=0.0002, and NHEJD/HRD p=0.0045).  
No correlation of cisplatin sensitivity was found with NHEJ function or inhibition (Figure 
4.C). Cisplatin was found to inhibit NHEJ significantly even at 4nM concentration (Figure 
4.D). This was consistent with the finding of no association of NHEJ function with 
progression free survival (PFS) or overall survival in our cohort of patients who were treated 
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with a standard platinum based therapy after a median follow up of 20 months Supplementary 
Table ST1.  
Protein expression of Ku70, Ku80 and DNAPK, but not DNA-PK phosphorylation, may 
serve as a biomarker of NHEJ function 
Analysis of NHEJ pathway components showed that protein expression of Ku70, Ku80 and 
DNA-PKcs, normalised to GAPDH, were all significantly lower in NHEJD cultures (Ku70 
p=0.0013, Ku80 p=0.002 and DNA-PKcs p<0.0001, figure 5.A). These were found to be 
good predictors (AUC 0.798, 0.762 and 0.852 respectively, figure 5.B) for NHEJ function 
and may therefore be suitable candidates for biomarkers. Discordance between protein and 
mRNA expression was noted, as previously reported in other studies [50, 51]. DNA-PK 
autophosphorylation correlated with NHEJ function in cell lines, but not in the PCO cultures 
(Supplementary figure S1).  
Interaction of HR and NHEJ pathways 
We have previously demonstrated that 50% of ovarian cultures are functionally HRD [28], 
therefore upon the finding that 40% of primary ovarian cancer cultures are also NHEJD we 
assessed the interaction of NHEJ and HR. The addition of the DNA-PK inhibitor, NU7441, 
resulted in a significant up-regulation of RAD51 foci after 2Gy irradiation in OSEC2 cells 
(Figure 6.A), demonstrating an increase in HR repair. NU7441 also recovered HR 
competence in the BRCA1 deficient cell line, but it had no effect in the HR competent or 
BRCA2 defective cell lines (Figure 6.B). Furthermore, the mean fold rise in RAD51 foci in 
DNA-PK deficient M059J cells was significantly higher compared to isogenic DNA-PK 
proficient M059FUS-1 cells (p < 0.0001, Figure 7.C).   
In our cohort of PCO cultures, NHEJ function was independent of HR competence. 15 
cultures were functional for both pathways, 7 cultures were defective for both pathways, 
while 11 and 14 cultures showed defects in NHEJ and HR respectively. RAD51 foci rise was 
higher in NHEJD compared to NHEJC cultures (p<0.0024, figure 7.A). DNA-PKcs 
expression was higher in HRC cultures compared to HRD cultures (p<0.0001, figure 7.A).). 
When taking both HR and NHEJ function into account, whilst both NHEJC/HRC and 
NHEJD/HRC were found to have RAD51 foci fold rise >2, the mean RAD51 foci fold rise 
for NHEJC/HRC group was lower compared to NHEJD/HRC group (Figure 7.B). The 
differences in RAD51 foci rise between all four groups was independent of the amount of 
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DNA DSBs, as determined by ƴH2AX foci formation. Importantly , no correlation between 
either PARP-1 activity or mRNA expression and HR or NHEJ competence was found 
(Supplementary figure 1.C).  
Discussion 
Here we have described our findings that NHEJ is defective in more than 40% of ex vivo 
EOCs. We found NHEJ to be independent of HR function and PARP-1 activity. In contrast to 
HR (where cells with the HRD phenotype are sensitive to PARPi) we have demonstrated that 
cells defective in NHEJ are resistant to PARPi. By considering the function of both pathways, 
we have shown that only the NHEJC/HRD cultures are sensitive to rucaparib. This finding 
potentially explains the resistance observed in some HRD tumours. Finally, we suggest that 
expression of the NHEJ related proteins Ku70, Ku80 and DNA-PKcs may be useful as 
biomarkers to determine NHEJ status in cancer samples. 
The sensitivity of HRD cancers to PARPi was initially attributed to the concept of synthetic 
lethality, based on the theory that HR defective cells are unable to repair DNA DSBs [25, 
52]. However, the majority of DNA DSBs are repaired by NHEJ [1, 15]. Furthermore, cell 
line studies demonstrate interaction between the NHEJ pathway, PARP-1 and subsequent 
resistance to PARPi [37]. The suggested role for NHEJ in PARPi sensitivity was through up 
regulation of error prone NHEJ in HRD cells [37]. Recent studies have demonstrated that the 
error prone A-EJ, functions in the absence of NHEJ and competes with HR [7, 8, 53]. Clearly 
the interaction between the various DSB repair pathways is complex and understanding is 
compounded by the commonality of the early part of the process. In this study we weren’t 
able to assess the cell cycle specific of both pathways but this may provide further insight 
into the interaction [54].  
Nevertheless,we have found that NHEJ function is independent of HR competence and that 
inhibition of NHEJ resulted in up regulation of HR function in HRC and BRCA1 deficient 
cells. In our cohort, the cultures which were NHEJD were resistant to rucaparib, irrespective 
of HR function. This is supported by the observation that NU7441 caused rucaparib 
resistance in all sensitive cultures, independent of HR function. When taking both pathways 
into account only NHEJC/HRD cultures were found to be sensitive to rucaparib. Here we 
demonstrate the role of NHEJ function in ex vivo primary cultures. Therefore, we propose 
that in EOC, in the absence of HR, error prone NHEJ results in sensitivity to PARPi. 
Conversely absence of NHEJ function results in PARPi resistance in HRD cells. This may be 
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through A-EJ, however assessment of this pathway in primary EOC is still needed. Due to the 
inhibitory effect of cisplatin on NHEJ [55], this model is limited to rucaparib sensitivity only. 
The hypothesis put forward for the role of NHEJ in PARPi resistance is based on the error 
proneness of NHEJ. The errors in repair are suggested to cause lethal defects in DNA, which, 
in the absence of HR, results in apoptosis. Therefore, NHEJC/HRD cells are sensitive to 
PARPi. Cells with competent NHEJ and HR pathways are able to repair DNA damage and 
are, therefore, resistant to PARPi. In the absence of NHEJ, the slower error free HR takes 
over repair. This notion is supported by findings of greater HR function, demonstrated by 
greater RAD51 foci formation in the DNA-PK deficient cell lines in this study as well as the 
existing literature [56]. Therefore, in the absence of NHEJ function, the lack of error prone 
repair results in resistance to PARPi [37]. 
Our finding of selectivity for a DNA-PKcs inhibitor to selectively revert the BRCA1 mutant 
cell line but not the BRCA2 mutant line is interesting but can be explained by the differing 
functions of BRCA1 and BRCA2 in the DDR pathways. The role of BRCA1 is to inhibit Rif1 
which in turn selects for NHEJ. HR can still therefore function in the absence of BRCA1 but 
preferentially cells will proceed down the NHEJ pathway because there is no inhibition of 
Rif1 and therefore no inhibition of NHEJ. But if NHEJ is inhibited or defective, even without 
BRCA1, HR can go ahead.  
The role of BRCA2 is within HR pathway itself. Therefore inhibiting NHEJ in the absence of 
BRCA2 still does not activate HR because HR itself is broken.   
The ability to select the correct patient, for the correct treatment, at the right time, is required 
for personalised medicine. Our findings suggest that accurate selection will be compromised 
if HR function alone is assessed and assessment of NHEJ may also be required. Whilst 
attempts are being made to develop predictive biomarkers of HR, we suggest that biomarkers 
for NHEJ should also be developed in order to aid patient selection for PARPi therapy. 
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Figure legends 
Figure 1. Rejoining of BstXI compatible (Co), 2 base mismatch (2I) and 4 base mismatch 
(4I) substrates. A. Rejoining of BstXI compatible (Co), 2 base mismatch (2I) and 4 base 
mismatch (4I) substrates with or without addition of λ substrate by T4ligase and OSEC2 cell 
line. Agarose gels are representative of 3 independent experiments. Successful rejoining is 
demonstrated by the presence of multimer bands. B. Densitometry quantification of OSEC2 
rejoining results are expressed as total rejoined products / total DNA loaded. Error bars are 
SEM. C. PCR analysis of rejoined DNA of BstXI Co or 2I substrates by V3YAC (DNA-
PKcs corrected), V3 (DNA-PKcs deficient), M059FUS-1 (DNA-PKcs corrected) andM059J 
(DNA-PKcs deficient) cell lines amplified using pFOR and pREV primers. Correct rejoining 
produces products of 551bps. Inaccurate rejoining with loss of bases results in smaller or no 
product formation. Gels are representative of 3 independent experiments. D. Rejoining of Co 
substrates by V3YAC and V3 cell lines with addition of increasing concentration of NU7741. 
Rejoining is demonstrated by formation of multimer bands. Gels are representative of three 
independent experiments.  
Figure 2. End joining by immortalised cell lines. A. End joining of compatible BstXI 
substrates by ovarian cell lines. Gels are representative of 3 independent experiments B. End 
joining of 2I BstXI substrates by ovarian cell lines. Gels are representative of 3 independent 
experiments. C. Intracellular end joining of linearised pGL2 vector by ovarian cell lines 
measured by luciferase expression. Measured as precise rejoining / overall end joining x 100. 
Data are average of three independent experiments. Error bars are SEM. D. Correlation of 
rejoining by the two assays.  
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Figure 3. End joining of BstXI substrates by PCO cultures. A. Quantification of PCO 
rejoining of Co substrates. Results are representative of 3 independent experiments. OSEC2 
and V3YAC (DNA-PKcs corrected) were used as positive controls. V3 (DNA-PKcs 
deficient) cell line was used as a negative control. Water was used as a contamination control. 
Error bars are SEM. PCO N = 47. B. Representative image of GelRed detection of end 
joining of BstXI compatible substrates by PCO cultures. C. Representative image of PCR 
analysis of rejoined DNA of Co and 2I substrates amplified using pFOR and pREV primers. 
Correct rejoining produces products of 551bps. Inaccurate rejoining with loss of bases results 
in smaller or no product formation. 
Figure 4. Rucaparib and cisplatin cytotoxicity in PCO cultures and cell lines. A. Cell survival 
calculated as cell growth after 10 days treatment with 10µM rucaparib as a fraction of DMSO 
control growth for PCO cultures was assessed by SRB assay and results were divided by 
NHEJ and HR status. Error bars are SEM. N = 47. In addition to treatment with rucaparib 
cells were also treated with 1µM NU7441 and normalised to DMSO controls. Results for 
cultures sensitive to rucaparib (< median survival) are presented. N = 22. B. Cell survival 
after 10 days treatment with 10µM rucaparib or 10µM cisplatin for immortalised cell lines 
assessed by SRB assay and results were divided by NHEJ status. Error bars are SEM. N = 8. 
C. Cell survival calculated as cell growth after 10 days treatment with 10µM cisplatin as a 
fraction of H2O control growth for PCO cultures was assessed by SRB assay and results were 
divided by NHEJ and HR status. Error bars are SEM. N = 42. In addition to treatment with 
cisplatin cells were also treated with 1µM NU7441 and normalised to DMSO control. N = 42. 
D. Cisplatin inhibition of end joining of compatible and incompatible BstXI digested 
substrates by OSEC2 cell line. Results are average of three independent experiments. Error 
bars are SEM.  
Figure 5. Prediction of NHEJ function by mRNA and protein expression of pathway 
components A. mRNA and protein expression of NHEJ components PCO cultures assessed 
by RT-qPCR and western blotting. Western bands were quantified using Fuji LAS-300 Image 
Analyser System. Protein and mRNA levels were normalised to GAPDH expression. Results 
are average of 3 independent experiments. Error bars are SEM. N = 47. B. ROC curves for 
Ku70, Ku80 and DNA-PKcs protein expression as predictors of NHEJ function. ROC curves 
were generated and AUC calculated using PRISM software.  
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Figure 6. The effect of DNA-PK inhibition on HR function. A. HR function after DNA-PK 
inhibition. RAD51 foci fold rise above un-irradiated controls over time after 2Gy irradiation 
in OSEC2 cell line +/- 1µM NU7441 treatment. Foci were counted across 3 fields of view for 
each sample counting >50 cells in each sample. Results are average of 3 independent 
experiments. B. HR competence assessed by a 2 fold increase in RAD51 foci formation 
above DMSO treated controls after 24 hours of 10 µM rucaparib and 2 Gy IR treatment in 
BRCA1 and BRCA2 deficient and proficient paired cell lines +/- 1µM NU7441. Cell lines 
used were UWB1-289 cell line which carries a germline BRCA1 mutation within exon 11 
and a deletion of the wild-type allele and paired UWB1.289+BRCA1 cell line in which wild 
type BRCA1 has been restored. BRCA2 paired cell lines were PEO1 which carries 5193C>G 
(Y1655X) BRCA2 mutation and PEO4 which was derived from the same patient and carries a 
secondary BRCA2 mutation [5193C>T (Y1655Y)] that restores BRCA2 function. RAD51 
foci were assessed as mean foci count per cell compared to untreated controls. Foci were 
counted across 3 fields of view for each sample counting >50 cells in each sample. Results 
are average of 3 independent experiments. Error bars are SEM. C. RAD51 and γH2AX focus 
formation was assessed 24 hrs after 2 Gy irradiation compared to untreated controls. Foci were 
counted across > 100 nuclei and results are expressed as fold rise above controls. 
Figure 7. Interaction of NHEJ and HR pathways in PCO cultures. A. RAD51 foci were 
assessed as mean foci count per cell in samples after 24 hours of 10 µM rucaparib and 2 Gy 
IR treatment. Foci were counted across 3 fields of view for each sample counting >50 cells in 
each sample. Results are expressed as fold rise above DMSO treated controls. DNA-PK 
protein expression was assessed by western blotting and normalised to GAPDH house keeper 
gene. Error bars are SEM. RAD51 foci and DNA-PK expression results were divided by 
NHEJ and HR function. B. DNA damage was assessed by ƴH2AX foci rise and HR function 
by RAD51 foci rise after 24 hours of 10 µM rucaparib and 2Gy IR treatment compared to 
DMSO treated controls. Results were divided by NHEJ and HR function. 
 







